Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 101–200 of 937
Foster, D. A., Yellen, P., Xu, L., & Saqcena, M. (2010) · Genes & Cancer · doi:10.1177/1947601910392989 · Cited by 275
Synergy between LRH-1 and β-Catenin Induces G1 Cyclin-Mediated Cell Proliferation
Botrugno, O. A., Fayard, E., Annicotte, J.-S., Haby, C., Brennan, T., Wendling, O., Tanaka, T., Kodama, T., Thomas, W., Auwerx, J., et al. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.07.009 · Cited by 273
Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression
Tashiro, E., Tsuchiya, A., & Imoto, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00449.x · Cited by 270
Development of mice expressing a single D-type cyclin
Ciemerych, M. A., Kenney, A. M., Sicinska, E., Kalaszczynska, I., Bronson, R. T., Rowitch, D. H., Gardner, H., & Sicinski, P. (2002) · Genes & Development · doi:10.1101/gad.1023602 · Cited by 267
“This idea is in agreement with our earlier observations, that in mammary epithelial cells, the Ras and Neu oncogenes can communicate with the cell cycle machinery only via cyclin D1, explaining the absolute dependency of Ras- and Neu-driven oncogenic pathways on cyclin D1 (Yu et al. 2001).”
ResultCyclin D1, EMS1 and 11q13 Amplification in Breast Cancer
Ormandy, C. J., Musgrove, E. A., Hui, R., Daly, R. J., & Sutherland, R. L. (2003) · Breast Cancer Research and Treatment · doi:10.1023/a:1023033708204 · Cited by 270
“Cyclin D1 is essential for the formation of lobuloalveoli during normal mammary gland development [34, 35] and is also essential for the promotion of carcinogenesis by the potent mammary oncogenes c-neu and v-Ha-ras [36], suggesting these as likely preferentially cooperating oncogenes.”
BackgroundSutherland, R. L., & Musgrove, E. A. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023591.45568.77 · Cited by 258
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
“(44, 45), so that a critical effector of HER2-mediated oncogenicity is removed.”
BackgroundProtein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
“For example, breast cancer that is driven by the ErbB2 oncogene is dependent on CDK4/cyclin D1 function and mice lacking cyclin D1 are resistant to ErbB2-driven mammary neoplasia (Yu et al. 2001 ; Landis et al. 2006).”
BackgroundMultiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy
Roberts, P. J., Bisi, J. E., Strum, J. C., Combest, A. J., Darr, D. B., Usary, J. E., Zamboni, W. C., Wong, K.-K., Perou, C. M., & Sharpless, N. E. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs002 · Cited by 255
PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells
Ryo, A., Liou, Y.-C., Wulf, G., Nakamura, M., Lee, S. W., & Lu, K. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5281-5295.2002 · Cited by 253
“More importantly, disruption of the cyclin D1 gene in mice completely suppresses the ability of Ha-Ras or c-Neu/ HER2 to induce tumor development in the mammary gland (60).”
BackgroundResultInfluentialHutchinson, J. N., Jin, J., Cardiff, R. D., Woodgett, J. R., & Muller, W. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3465 · Cited by 251
“Indeed, Cyclin D1 is up-regulated in 50% of mammary tumors (37) and is essential for ErbB-2-mediated tumor progression (38).”
BackgroundChu, I., Blackwell, K., Chen, S., & Slingerland, J. (2005) · Cancer Research · doi:10.1158/0008-5472.18.65.1 · Cited by 251
“Cyclin D1 deficient mice are resistant to breast cancers induced by transgenic ErbB2/neu (43) suggesting a critical role of cyclin D1 in ErbB2 mediated tumorigenesis.”
BackgroundERK MAP kinase in G1 cell cycle progression and cancer
Torii, S., Yamamoto, T., Tsuchiya, Y., & Nishida, E. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00244.x · Cited by 250
Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation
Gautschi, O., Ratschiller, D., Gugger, M., Betticher, D. C., & Heighway, J. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2006.09.024 · Cited by 243
ID genes mediate tumor reinitiation during breast cancer lung metastasis
Gupta, G. P., Perk, J., Acharyya, S., de Candia, P., Mittal, V., Todorova-Manova, K., Gerald, W. L., Brogi, E., Benezra, R., & Massagué, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709185104 · Cited by 247
Phosphorylation-specific prolyl isomerization: is there an underlying theme?
Wulf, G., Finn, G., Suizu, F., & Lu, K. P. (2005) · Nature Cell Biology · doi:10.1038/ncb0505-435 · Cited by 238
“Because cyclin D1 is an important cell-cycle regulator that is known to have a key role in the development of many cancer”
BackgroundMaroulakou, I. G., Oemler, W., Naber, S. P., & Tsichlis, P. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3782 · Cited by 238
“Neu transgene as described previously (31).”
Heterogeneity in Cancer Metabolism: New Concepts in an Old Field
Gentric, G., Mieulet, V., & Mechta-Grigoriou, F. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6750 · Cited by 240
Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy1
Luan, F. L., Hojo, M., Maluccio, M., Yamaji, K., & Suthanthiran, M. (2002) · Transplantation · doi:10.1097/00007890-200205270-00008 · Cited by 235
“cell-cycle arrest at G1 phase(26), whereas loss of p27 kip1 or over-expression of cyclin D1 has been linked to tumor growth and metastatic progression (27, 28).”
BackgroundSkeen, J. E., Bhaskar, P. T., Chen, C.-C., Chen, W. S., Peng, X.-D., Nogueira, V., Hahn-Windgassen, A., Kiyokawa, H., & Hay, N. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.022 · Cited by 234
“Furthermore, cyclin D1 KO MEFs are not impaired in their ability to be transformed by activated Ras (Yu et al., 2001).”
BackgroundCell Cycle Arrest and Repression of Cyclin D1 Transcription by INI1/hSNF5
Zhang, Z.-K., Davies, K. P., Allen, J., Zhu, L., Pestell, R. G., Zagzag, D., & Kalpana, G. V. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.16.5975-5988.2002 · Cited by 233
“Cyclin D1 overexpression has been found in various tumors, including human breast cancer tumors, and repressing its expression makes the tumor cells exit from G1 phase of cell cycle, thereby reversing the tumor characters (49).”
BackgroundThe role of Rho GTPases in disease development
Boettner, B., & Van Aelst, L. (2002) · Gene · doi:10.1016/s0378-1119(02)00426-2 · Cited by 229
Boonyaratanakornkit, V., McGowan, E., Sherman, L., Mancini, M. A., Cheskis, B. J., & Edwards, D. P. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0337 · Cited by 222
“Cyclin D1 as a progesterone target gene regulated in this manner is of potential relevance because it is required for normal mammary gland development (54), is frequently overexpressed in breast cancer (55), its overexpression in mice promotes development of mammary tumors (56), and inactivation of cyclin D1 protects…”
BackgroundCyclins and Cell Cycle Control in Cancer and Disease
Casimiro, M. C., Crosariol, M., Loro, E., Li, Z., & Pestell, R. G. (2012) · Genes & Cancer · doi:10.1177/1947601913479022 · Cited by 216
Solomon, D. A., Wang, Y., Fox, S. R., Lambeck, T. C., Giesting, S., Lan, Z., Senderowicz, A. M., & Knudsen, E. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303969200 · Cited by 218
Physiological Relevance of Cell Cycle Kinases
Malumbres, M. (2011) · Physiological Reviews · doi:10.1152/physrev.00025.2010 · Cited by 213
“Sicinski group showed that cyclin D1 is required for Rasbut not Myc-induced breast tumors (366), and this requirement was later attributed to the cyclin D1-dependent kinase activity of Cdk4 (184, 210, 367).”
BackgroundEvidence That SOX2 Overexpression Is Oncogenic in the Lung
Lu, Y., Futtner, C., Rock, J. R., Xu, X., Whitworth, W., Hogan, B. L. M., & Onaitis, M. W. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011022 · Cited by 212
“Finally, Cyclin D1 is necessary to effect transformation of cells downstream of specific oncogenic stimuli [30].”
BackgroundRoy, P. G., & Thompson, A. M. (2006) · The Breast · doi:10.1016/j.breast.2006.02.005 · Cited by 210
A role for the scaffolding adapter GAB2 in breast cancer
Bentires-Alj, M., Gil, S. G., Chan, R., Wang, Z. C., Wang, Y., Imanaka, N., Harris, L. N., Richardson, A., Neel, B. G., & Gu, H. (2006) · Nature Medicine · doi:10.1038/nm1341 · Cited by 213
Wang, C., Li, Z., Lu, Y., Du, R., Katiyar, S., Yang, J., Fu, M., Leader, J. E., Quong, A., Novikoff, P. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603363103 · Cited by 208
Angelis, P. M. D., Kravik, K., Tunheim, S. H., Haug, T., & Reichelt, W. H. (2004) · Molecular Cancer · doi:10.1186/1476-4598-3-11 · Cited by 210
The NF-κB/IκB signaling system: A molecular target in breast cancer therapy
Wu, J. T., & Kral, J. G. (2005) · Journal of Surgical Research · doi:10.1016/j.jss.2004.06.006 · Cited by 205
CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis
Lazarov, M., Kubo, Y., Cai, T., Dajee, M., Tarutani, M., Lin, Q., Fang, M., Tao, S., Green, C. L., & Khavari, P. A. (2002) · Nature Medicine · doi:10.1038/nm779 · Cited by 203
Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis
Wulf, G., Garg, P., Liou, Y., Iglehart, D., & Lu, K. P. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600323 · Cited by 203
“…breast cancers induced by oncogenic Neu or Ras, but not Myc in vivo We next examined the effects of Pin1 function on the incidence of mammary carcinomas by monitoring virgin mice that carried one copy of MMTV-c-Neu or -v-Ha-Ras transgene on either Pin1þ /þ , Pin1þ / or Pin / background over time.”
BackgroundMethodResultInfluentialCDK4: A Key Player in the Cell Cycle, Development, and Cancer
Baker, S. J., & Reddy, E. P. (2012) · Genes & Cancer · doi:10.1177/1947601913478972 · Cited by 194
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer
Torres-Guzmán, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., McNulty, A. M., Gong, X., Boehnke, K., Du, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17778 · Cited by 196
“CDK4 and Cyclin D1 may be especially relevant for breast cancer, since evidence suggests that both are important oncogenic drivers for this disease [4, 9, 10, 12, 26].”
BackgroundA Critical Role for FBXW8 and MAPK in Cyclin D1 Degradation and Cancer Cell Proliferation
Okabe, H., Lee, S.-H., Phuchareon, J., Albertson, D. G., McCormick, F., & Tetsu, O. (2006) · PLoS ONE · doi:10.1371/journal.pone.0000128 · Cited by 198
“As a result, it is a potential target for cancer therapeutics [2].”
Cyclin D1 Repression of Peroxisome Proliferator-Activated Receptor γ Expression and Transactivation
Wang, C., Pattabiraman, N., Zhou, J. N., Fu, M., Sakamaki, T., Albanese, C., Li, Z., Wu, K., Hulit, J., Neumeister, P., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.17.6159-6173.2003 · Cited by 196
“In mammary tumors induced by mammary tissue-targeted oncogenes (ErbB2, Ras, and Src), the relative abundance of cyclin D1 was increased and that of PPAR was decreased compared with results for normal mammary epithelium (Fig.”
BackgroundHocker, T. L., Singh, M. K., & Tsao, H. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.226 · Cited by 189
“Moreover, the oncogenic effects of Ras in breast cancer are entirely dependent on cyclin D1, and that mice lacking cyclin D1 are resistant to breast cancers induced by the Neu and Ras oncogenes (Yu et al., 2001).”
BackgroundTargeting the cell cycle in breast cancer: towards the next phase
Thu, K., Soria-Bretones, I., Mak, T., & Cescon, D. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1502567 · Cited by 185
Cyclin D1 Determines Mitochondrial Function InVivo
Sakamaki, T., Casimiro, M. C., Ju, X., Quong, A. A., Katiyar, S., Liu, M., Jiao, X., Li, A., Zhang, X., Lu, Y., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02074-05 · Cited by 183
“Premature senescence induced by oncogenic signals such as Ras or ErbB2 must be sequentially bypassed for cellular transformation to occur.”
BackgroundInfluentialKuang, S.-Q., Liao, L., Zhang, H., Lee, A. V., O’Malley, B. W., & Xu, J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3745 · Cited by 182
“Because the ras oncoprotein acts through the MAPK pathway to induce cyclin D1 production (36, 37), we examined the levels of total and activated MAPK proteins by immunoblotting using specific antibodies against total and phosphorylated p42 and p44 MAPK proteins (38).”
MethodThe Putative Oncoprotein Bcl-3 Induces Cyclin D1 To Stimulate G1 Transition
Westerheide, S. D., Mayo, M. W., Anest, V., Hanson, J. L., & Baldwin, A. S. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.24.8428-8436.2001 · Cited by 182
“In addition, cyclin D1 is required for the malignant transformation of human mammary epithelial cells by Her-2/Neu and Ras (39).”
BackgroundOverview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present
Casimiro, M. C., Velasco-Velázquez, M., Aguirre-Alvarado, C., & Pestell, R. G. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.867017 · Cited by 184
“However, cyclin D1 mice remain fully sensitive to c-Myc or Wnt-1 oncogenic pathways of the mammary epithelium [58-60].”
BackgroundSpring, L. M., Zangardi, M. L., Moy, B., & Bardia, A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0142 · Cited by 178
“HER2-induced cellular proliferation is mediated via the CDK4/ 6–Rb axis, and knockdown of cyclin-D in mice makes them resistant to tumors induced by the neu oncogene [24].”
BackgroundCellular senescence and the tumour microenvironment
Takasugi, M., Yoshida, Y., & Ohtani, N. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13268 · Cited by 172
Contributions of Myc to tumorigenesis
Lutz, W., Leon, J., & Eilers, M. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00036-7 · Cited by 177
Frequent amplification of 8q24, 11q, 17q, and 20q‐specific genes in pancreatic cancer
Mahlamäki, E. H., Bärlund, M., Tanner, M., Gorunova, L., Höglund, M., Karhu, R., & Kallioniemi, A. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10122 · Cited by 175
“A recent study showed that CCND1-deficient mice were resistant to breast cancers induced by the ERBB2 and HRAS oncogenes (Yu et al., 2001).”
BackgroundCyclin D1 Regulates Cellular Migration through the Inhibition of Thrombospondin 1 and ROCK Signaling
Li, Z., Wang, C., Jiao, X., Lu, Y., Fu, M., Quong, A. A., Dye, C., Yang, J., Dai, M., Ju, X., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02124-05 · Cited by 177
“Furthermore, cyclin D1-deficient mice are resistant to gastrointestinal tumors induced by mutation of the Apc gene (28) or tumor formation induced by either mammary-targeted Ras or ErbB2 (82).”
BackgroundRole of Rho-family proteins in cell adhesion and cancer
Malliri, A., & Collard, J. G. (2003) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(03)00098-x · Cited by 172
Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer
Ryo, A., Liou, Y.-C., Lu, K. P., & Wulf, G. (2003) · Journal of Cell Science · doi:10.1242/jcs.00276 · Cited by 173
“In common with many other E2F-target genes (Fry et al., 1997; Nevins, 2001; Ohtani et al., 1995), PIN1 transcription and its protein levels fluctuate during cell cycle progression in non-neoplastic cells (Ryo et al., 2002) but not in transformed cells (Shen et al., 1998).”
BackgroundInfluentialWnt signalling and the mechanistic basis of tumour development
Ilyas, M. (2005) · The Journal of Pathology · doi:10.1002/path.1692 · Cited by 170
“However, Wnt1 transgenic mice also develop mammary tumours which, despite the fact that cyclin D1 is a well-described target of β-catenin, will develop in the absence of functional cyclin D1 [129].”
BackgroundHanai, J., Doro, N., Sasaki, A. T., Kobayashi, S., Cantley, L. C., Seth, P., & Sukhatme, V. P. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.22895 · Cited by 165
“Somatic gene alterations leading to the inactivation of the tumor suppressor gene PTEN and gain-of-function mutations targeting PIK3CA (the gene encoding the catalytic phosphoinositide-3 kinase subunit p110a) have been described (Yuan and Cantley, 2008).”
BackgroundUpdates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Sobhani, N., D’Angelo, A., Pittacolo, M., Roviello, G., Miccoli, A., Corona, S. P., Bernocchi, O., Generali, D., & Otto, T. (2019) · Cells · doi:10.3390/cells8040321 · Cited by 167
“For instance, mice lacking cyclin D1 or CDK4, as well as mice expressing mutant cyclin D1 (incapable of activating CDK4/6) were resistant to breast cancer induced by the Erbb2/HER2 oncogene [34,63,64].”
BackgroundCell cycle, cytoskeleton dynamics and beyond: the many functions of cyclins and CDK inhibitors
Bendris, N., Lemmers, B., & Blanchard, J. M. (2015) · Cell Cycle · doi:10.1080/15384101.2014.998085 · Cited by 166
“Conversely, mice with ablation in the mammary gland of the gene coding for cyclin D1 are resistant to transformation by Erb-B2/neu and Ras even though they remain sensitive to other transformation pathways.(28) Curiously enough we should also stress at this stage the altered regulation of G1 cyclins in human fibroblas…”
BackgroundRosner, A., Miyoshi, K., Landesman-Bollag, E., Xu, X., Seldin, D. C., Moser, A. R., MacLeod, C. L., Shyamala, G., Gillgrass, A. E., & Cardiff, R. D. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64269-1 · Cited by 168
Cicatiello, L., Addeo, R., Sasso, A., Altucci, L., Petrizzi, V. B., Borgo, R., Cancemi, M., Caporali, S., Caristi, S., Scafoglio, C., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7260-7274.2004 · Cited by 164
“against breast cancer induced by neu and ras oncogenes (66).”
BackgroundCyclins and CDKS in development and cancer: lessons from genetically modified mice
Santamaria, D. (2006) · Frontiers in Bioscience · doi:10.2741/1871 · Cited by 165
PRL Activates the Cyclin D1 Promoter Via the Jak2/Stat Pathway
Brockman, J. L. (2002) · Molecular Endocrinology · doi:10.1210/me.16.4.774 · Cited by 163
Rivas, M. A., Carnevale, R. P., Proietti, C. J., Rosemblit, C., Beguelin, W., Salatino, M., Charreau, E. H., Frahm, I., Sapia, S., Brouckaert, P., et al. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.10.005 · Cited by 161
“It has recently been demonstrated that cyclin D1 is a requirement for breast carcinogenesis [51], and that NF-κB promotes G1-to-S-phase transition in T47D human mammary carcinoma cells through regulation of cyclin D1 expression [30,52].”
BackgroundSignaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens.
Thiantanawat, A., Long, B. J., & Brodie, A. M. H. (2003) · PubMed · Cited by 191
Complexities in the development of cyclin-dependent kinase inhibitor drugs
Sausville, E. A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02308-0 · Cited by 160
Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance
Taneja, P., Maglic, D., Kai, F., Zhu, S., Kendig, R. D., Elizabeth, A., & Inoue, K. (2010) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s4773 · Cited by 198
Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer
Cohen, B., Shimizu, M., Izrailit, J., Ng, N. F. L., Buchman, Y., Pan, J. G., Dering, J., & Reedijk, M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0621-9 · Cited by 159
NF-κB in Mammary Gland Development and Breast Cancer
Cao, Y., & Karin, M. (2003) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1025905008934 · Cited by 158
“Importantly, transgenic overexpression of cyclin D1 in the mammary gland was shown to increase the incidence of mammary carcinomas (57), and ablation of cyclin D1 gene protects mice against breast cancers induced by MMTV-neu or MMTV-v-Ha-ras (58).”
Mammary epithelial cell transformation: Insights from cell culture and mouse models
Dimri, G., Band, H., & Band, V. (2005) · Breast Cancer Research · doi:10.1186/bcr1275 · Cited by 120
“viral proteins, such as SV40 large T, polyoma virus T antigen [56-58], or cellular proteins such as c-Myc, ErbB2/neu, cyclin D1, cyclin E, ERs, mutant p53, c-Ha-ras, and Wnt-1 [59-63].”
BackgroundInfluentialBridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
Xiong, Y., Zhong, Y., Yim, H., Yang, X., Park, K.-S., Xie, L., Poulikakos, P. I., Han, X., Xiong, Y., Chen, X., et al. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09255 · Cited by 154
Kaye, F. J. (2002) · Oncogene · doi:10.1038/sj.onc.1205834 · Cited by 153
“…the resistance of cyclin D1 null murine breast tissues to the tumorigenic effects of neu over-expression, but not to the effects of ectopic Myc (Yu et al., 2001), also correlates with the absence of neu amplification (Franklin et al., 2002; Hirsch et al., 2002), but the frequent…”
BackgroundInfluentialAmit, S., & Ben‐Neriah, Y. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00096-2 · Cited by 160
Cyclin D1 Governs Adhesion and Motility of Macrophages
Neumeister, P., Pixley, F. J., Xiong, Y., Xie, H., Wu, K., Ashton, A., Cammer, M., Chan, A., Symons, M., Stanley, E. R., et al. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.02-07-0102 · Cited by 151
“…mice overexpressing cyclin D1 in the mammary gland develop mammary cancer (Wang et al., 1994), whereas mice lacking cyclin D1 are resistant to oncogene-induced tumorigenesis, including Ras-induced skin tumors (Robles et al., 1998) and ErbB2 or Ras-induced mammary tumor formation (Yu et al., 2001).”
BackgroundInfluentialWatt, A. C. S., & Goel, S. (2022) · Breast Cancer Research · doi:10.1186/s13058-022-01510-6 · Cited by 173
“For example, cyclin D1 is required for mammary epithelial proliferation in pregnancy [18, 19], and knockout of either cyclin D1 or CDK4 prevents the development of mammary carcinomas from luminal epithelial cells driven by particular oncogenes, such as Neu or Ras, in mice [2, 3].”
BackgroundCell cycle in mouse development
Ciemerych, M. A., & Siciński, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208608 · Cited by 172
“Cyclin D1-deficient mice were resistant to breast cancers driven by the activated Ras and c-ErbB-2 oncogenes, while being fully susceptible to mammary carcinomas triggered by the Myc and Wnt-1 (Yu et al., 2001).”
BackgroundInfluentialBenzeno, S., Narla, G., Allina, J., Cheng, G. Z., Reeves, H. L., Banck, M. S., Odin, J. A., Diehl, J. A., Germain, D., & Friedman, S. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2818 · Cited by 153
“Additionally, because deregulated expression of cyclin D1 directly contributes to tumorigenesis in a number of animal model systems (16, 17), inhibition of cyclin D1 function may be an important target of cancer prevention and therapy (18).”
BackgroundThe long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma
Wu, Y., Liu, H., Shi, X., Yao, Y., Yang, W., & Song, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3247 · Cited by 150
“Cyclin D1 is one of the most important cell cycle regulatory proteins, playing pivotal roles in the development of a subset of human cancers including lung cancer [32, 33].”
BackgroundCao, Y., Luo, J.-L., & Karin, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706728104 · Cited by 148
Cyclins: Roles in mitogenic signaling and oncogenic transformation: Mini Review
Musgrove, E. A. (2006) · Growth Factors · doi:10.1080/08977190500361812 · Cited by 149
“Similarly, mice that have cyclin E “knocked-in” to the cyclin D1 locus develop Neu-induced mammary tumours at a rate similar to wild-type, indicating that cyclin E expression can compensate for the absence of cyclin D1 during oncogenesis.”
BackgroundInfluentialSchoonjans, K., Dubuquoy, L., Mebis, J., Fayard, E., Wendling, O., Haby, C., Geboes, K., & Auwerx, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409756102 · Cited by 148
Kang, J., Sergio, C. M., Sutherland, R. L., & Musgrove, E. A. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-32 · Cited by 152
“CDK4-deficient mice were resistant to skin tumour development induced by MYC [15], whereas mice lacking cyclin D1 expression and consequently lacking CDK4 activation still developed mammary tumours induced by MYC activation [51], strongly arguing that the requirement for CDK4 activity in MYC-induced tumorigenesis is a…”
BackgroundSteroid Receptors and Cell Cycle in Normal Mammary Epithelium
Anderson, E., & Clarke, R. B. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023584.01750.16 · Cited by 175
“These show that deletion of the cyclin D1 gene seriously impairs lobulo-alveolar development of the mammary gland in early pregnancy, which prevents lactation and confers resistance to mammary tumor induction by some (c-neu and v-Ha-ras) but not all oncogenes (62,63).”
BackgroundThe activities of cyclin D1 that drive tumorigenesis
Ewen, M. E., & Lamb, J. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.02.005 · Cited by 162
Bergmann, S., Royer-Pokora, B., Fietze, E., Jürchott, K., Hildebrandt, B., Trost, D., Leenders, F., Claude, J.-C., Theuring, F., Bargou, R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4056 · Cited by 145
“c-MYC induces mammary tumorigenesis by a preferred pathway involving spontaneous Kras2 mutations (30), and the oncogenic activity of ErbB2 in mammary epithelium is absolutely dependent on the presence of cyclin D1 protein, demonstrating that the ErbB2 pathway is connected to the cell cycle machinery by cyclin D1 (28).”
BackgroundLapillonne, H., Konopleva, M. Y., Tsao, T., Gold, D. L., McQueen, T. J., Sutherland, R. L., Madden, T. L., & Andreeff, M. (2003) · PubMed · Cited by 160
Hulit, J., Wang, C., Li, Z., Albanese, C., Rao, M., Di Vizio, D., Shah, S., Byers, S. W., Mahmood, R., Augenlicht, L. H., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7598-7611.2004 · Cited by 142
“Mice nullizygous for cyclin D1, which have abolished cyclin D1 abundance, are resistant to breast tumorigenesis induced by Ras or ErbB2.”
BackgroundInfluentialZou, X., Ray, D., Aziyu, A., Christov, K., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 142
“However, it has been shown that 3T3-immortalized cyclin D1-null MEF clones are sensitive to Ras-induced transformation (Yu et al. 2001).”
BackgroundShvarts, A., Brummelkamp, T. R., Scheeren, F., Koh, E., Daley, G. Q., Spits, H., & Bernards, R. (2002) · Genes & Development · doi:10.1101/gad.929302 · Cited by 140
“Other genes that depend on cyclin D1 for oncogenic activity include ras and neu, whereas oncogenes like c-myc and Wnt-1 do not require cyclin D1 as a downstream target (Robles et al. 1998; Yu et al. 2001).”
BackgroundOstrander, J. H., Daniel, A. R., Lofgren, K. A., Kleer, C. G., & Lange, C. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3409 · Cited by 141
Key signaling nodes in mammary gland development and cancer: β-catenin
Incassati, A., Chandramouli, A., Eelkema, R., & Cowin, P. (2010) · Breast Cancer Research · doi:10.1186/bcr2723 · Cited by 162
The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, C. G., & Dickler, M. N. (2015) · The Oncologist · doi:10.1634/theoncologist.2014-0443 · Cited by 135
Shields, J. M., Rogers-Graham, K., & Der, C. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110086200 · Cited by 147
Williams, T. M., Cheung, M. W.-C., Park, D. S., Razani, B., Cohen, A. W., Muller, W. J., Di Vizio, D., Chopra, N. G., Pestell, R. G., & Lisanti, M. P. (2003) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-08-0503 · Cited by 138
“Cyclin D1 is an important cell cycle regulator and has been shown to be overexpressed in a variety of human neoplasms, including breast cancers (Yu et al., 2001).”
BackgroundInfluentialControl of Cyclin D1 and Breast Tumorigenesis by the EglN2 Prolyl Hydroxylase
Zhang, Q., Gu, J., Li, L., Liu, J., Luo, B., Cheung, H.-W., Boehm, J. S., Ni, M., Geisen, C., Root, D. E., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.029 · Cited by 139
“…an important role in many forms of cancer, including breast cancer, and is induced by estrogen in estrogenreceptor positive breast cancers (Bartkova et al., 1994; Landis et al., 2006; Roy and Thompson, 2006; Yu et al., 2001), we asked whether EglN2 activity affects Cyclin D1 activity.”
Kobayashi, S., Shimamura, T., Monti, S., Steidl, U., Hetherington, C. J., Lowell, A. M., Golub, T., Meyerson, M., Tenen, D. G., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2318 · Cited by 135
Location, location, location: The role of cyclin D1 nuclear localization in cancer
Gladden, A. B., & Diehl, J. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20613 · Cited by 136
“The most striking result being that ablation of cyclin D1 prevents Ras- and Neu-dependent mammary cancer development [Yu et al., 2001].”
BackgroundForm and Function: how Estrogen and Progesterone Regulate the Mammary Epithelial Hierarchy
Arendt, L. M., & Kuperwasser, C. (2015) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-015-9337-0 · Cited by 159
“PI-MECs may also serve as the cellular precursors to MMTV-ErbB2 driven tumorigenesis [140–143].”
BackgroundInfluentialThe Wnt/β-Catenin Signaling Pathway as a Target in Drug Discovery
Takahashi-Yanaga, F., & Sasaguri, T. (2007) · Journal of Pharmacological Sciences · doi:10.1254/jphs.cr0070024 · Cited by 133
Understanding and overcoming tumor heterogeneity in metastatic breast cancer treatment
Pasha, N., & Turner, N. C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00229-1 · Cited by 143
Hodges-Gallagher, L., Cook, J., Lobenhofer, E. K., Li, L., Bennett, L., Bushel, P. R., Aldaz, C. M., Afshari, C. A., & Walker, C. L. (2003) · PubMed · Cited by 146
Civenni, G., Holbro, T., & Hynes, N. E. (2003) · EMBO reports · doi:10.1038/sj.embor.embor735 · Cited by 132
“Interestingly, increased levels of cyclin D2 have been found in mammary tumours arising in MMTV-Wnt1 transgenics (Yu et al., 2001), suggesting that cyclin D2 could be a direct target of Wnt1 in mammary cells.”
BackgroundClark, A. S., Karasic, T. B., DeMichele, A. M., Vaughn, D. J., O’Hara, M. H., Perini, R. F., Zhang, P. J., Lal, P., Feldman, M. D., Gallagher, M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4701 · Cited by 144
Molecular Aspects of the Mammalian Cell Cycle and Cancer
Sandal, T. (2002) · The Oncologist · doi:10.1634/theoncologist.7-1-73 · Cited by 152
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.